Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

22 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Mallinckrodt Articles

Actavis settles with Mallinckrodt over Exalgo 32mg; Teva gains FDA OK for Adderall XR

14 February 2013

Mallinckrodt Medical to distribute Rapiscan in France, Italy, Belgium, and Spain

11 February 2013

Covidien files Form 10 registration statement for planned spin-off of Pharma business

4 February 2013

Nuvo Research in patent settlement over Pennsaid

29 January 2013

Mallinckrodt to acquire CNS Thera for $100 million; Mediq to sell out for 775 million euros

25 September 2012

News briefs: Meda's Edluar; Debiopharm/Ascepion; Mallinckrodt/Horizon

19 June 2012

Watson settles over Exalgo; gets favorable news on enoxaparin

29 January 2012

Watson buys rights to Gedeon Richter’s Esmya; confirms Exalgo patent challenge

16 December 2010

Mallinckrodt Baker/Rubicon in excipient deal

1 September 2008

Ranbaxy revises target on US sales

14 July 2003

Showing 1-10 of 10 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • Is failure to adopt business process management putting the pharma industry at risk?
  • Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
  • New Zealand declines Alexion's funding application for Solaris
  • HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
  • Elan makes "transformational" acquisitions and a divestment
  • Is failure to adopt business process management putting the pharma industry at risk?
  • Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
  • New Zealand declines Alexion's funding application for Solaris
  • HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
  • Elan makes "transformational" acquisitions and a divestment

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS